Single-arm, open label, multicenter clinical study to evaluate the handling and safety of AVT06 pre-filled syringe (PFS) in subjects with chorioretinal vascular disease followed by an optional extension phase of AVT06 pre-filled syringe (PFS).

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505225-13-00

Acronym

AVT06-GL-D01

Enrollment

Registered

2023-11-06

Start date

2024-03-11

Completion date

2025-03-18

Last updated

2025-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chorioretinal vascular disease (neovascular age-related macular degeneration [nAMD], diabetic macular edema [DME], myopic choroidal neovascularization [CNV], retinal vein occlusion [RVO] and diabetic retinopathy [DR])

Brief summary

1. Proportion of AVT06 injections successfully administered with PFS at Day 1. 2. Incidence of ocular TEAEs, AESIs, and SAEs associated with the study eye from Baseline to Week 4.

Interventions

DRUGAflibercept

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1. Proportion of AVT06 injections successfully administered with PFS at Day 1. 2. Incidence of ocular TEAEs, AESIs, and SAEs associated with the study eye from Baseline to Week 4.	—

Countries

Latvia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026